The Effect of Intravitreal Injection of Anti-VEGF on Macular Edema and Visual Acuity, after Central Retinal Vein Occlusion
Abstract
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder which affect the patient visual ability. Visual prognosis depends on the type of retinal vein occlusion, that can be ischemic or non-ichemic, its severity, degree of retinal ischemia or macular edema and development of complications. The two most frequent complications of CRVO are persistent macular edema and neovascularization. One of the best and effective treatment for macular edema and neovascularisation seems to be intra vitreal anti-VEGF. Case report: We report 3 cases of CRVO with macular edema, treated with 3 intavitreal aflibercept (EYLEA) in 3 months. The Visual acuity (VA) improved on all 3 cases after each injection. This article aims to review the effect of anti-VEGF drugs in macular edema and improving vision in patients with CRVO.
Keywords: CRVO, macular edema, coroidal neovascularisation, visual acuity, anti-VEGF treatment.
References
A. Pielen, N. Feltgen, C. Isserstedt, J. Callizo, B. Junker, and C. Schmucker, “Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review,” PloS One, vol. 8, no. 10, article e78538, 2013.
T. Braithwaite, A. A. Nanji, K. Lindsley, and P. B. Greenberg, “Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion,” Cochrane Database of Systematic Reviews, no. 5, article CD007325, 2014.
A. R. Berger, A. F. Cruess, F. Altomare et al., “Optimal treatment of retinal vein occlusion: Canadian expert consensus,” Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 234, pp. 6–25, 2015.
P. A. Campochiaro, J. S. Heier, L. Feiner et al., “Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, pp. 1102.e1–1112.e1, 2010.
F. G. Holz, J. Roider, Y. Ogura et al., “VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study,” The British Journal of Ophthalmology, vol. 97, pp. 278–284, 2013.
J. F. Korobelnik, F. G. Holz, J. Roider et al., “Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study,” Ophthalmology, vol. 121, pp. 202–208, 2014.
Y. Ogura, J. Roider, J. F. Korobelnik et al., “Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study,” American Journal of Ophthalmology, vol. 158, no. 5, pp. 1032–1038, 2014.
D. Boyer, J. Heier, D. M. Brown et al., “Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study,” Ophthalmology, vol. 119, pp. 1024–1032, 2012.
D. M. Brown, J. S. Heier, W. L. Clark et al., “Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study,” American Journal of Ophthalmology, vol. 155, pp. 429.e7–437.e7, 2013.
Germany Ophthalmology Society and Retina Society, “Professional Asociation of German Ophthalmologists. [statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies],” Ophthalmol Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, vol. 109, pp. 818–831, 2012.
A. Bajor, A. Pielen, and L. Danzmann, “Retinal vein occlusion-which treatment when?” Klinische Monatsblätter für Augenheilkunde, 2017.
N. Feltgen and A. Pielen, “Retinal vein occlusion: therapy of retinal vein occlusion,” Ophthalmology Zeitchrift Deutschen Ophthalmologischen Gesellschaft, vol. 112, pp. 695–704, 2015.
G. Coscas, A. Loewenstein, A. Augustin et al., “Management of retinal vein occlusion—consensus document,” Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 226, pp. 4–28, 2011.
J. S. Pulido, C. J. Flaxel, R. A. Adelman, L. Hyman, J. C. Folk, and T. W. Olsen, “Retinal vein occlusions preferred practice pattern(®) guidelines,” Ophthalmology, vol. 123, pp. 182–208, 2016.
C. Chiquet, A. M. Bron, M. Straub et al., “Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up,” Ophthalmic Research, vol. 55, pp. 152–158, 2016.
“Study of comparative treatments for retinal vein occlusion 2 (SCORE2) October 2016 https://clinicaltrials.gov/ct2/show/NCT01969708?term=aflibercept+retinal+vein+occlusion&rank=3.
Downloads
Published
How to Cite
Issue
Section
License
Declaration/Copyright transfer:
1. In consideration of the undertaking set out in paragraph 2, and upon acceptance by ANGLISTICUM for publication of the manuscript in the Journal, I/We hereby assign and transfer publication rights to ANGLISTICUM, whereas I/We retain the copyright for the manuscript. This assignment provides ANGLISTICUM the sole right and responsibility to publish the manuscript in its printed and online version, and/or in other media formats.
2. In consideration of this assignment, ANGLISTICUM hereby undertakes to prepare and publish the manuscript in the Journal, subject only to its right to refuse publication if there is a breach of the Author’s warranty in paragraph 4 or if there are other reasonable grounds.
3. Editors and the editorial board of ANGLISTICUM are empowered to make such editorial changes as may be necessary to make the Manuscript suitable for publication.
4. I/We hereby acknowledge that: (a) The manuscript submitted is an original work and that I/We participated in the work substantively and thus I/We hereby are prepared to take public responsibility for the work; (b) I/We hereby have seen and approved the manuscript as submitted and that the manuscript has not either been published, submitted or considered for publication elsewhere; (c) The text, illustration, and any other materials included in the manuscript do not infringe upon any existing copyright or other rights of anyone.
5. I/We hereby indemnify ANGLISTICUM and the respective Editors of the Journal as mentioned in paragraph 3, and hold them harmless from any loss, expense or damage occasioned by a claim or suit by a third party for copyright infringement, or any suit arising out of any breach of the foregoing warranties as a result of publication of the manuscript.